[3]Rosenstock,J.,et al.,Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea:The PIONEER 3 Randomized Clinical Trial....
[15]Ji L, Agesen RM, Bain SC, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa...
[6]. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial[J]. JAMA, 2019,321(15):1466-1480. doi...
ObjectiveTo investigate the efficacy and safety of oral semaglutide in Chinese patients with type 2 diabetes mellitus(T2DM) inadequately controlled by diet and exercise only. MethodsIn the randomized, double-blind, multicenter, multinational PIONEER-11 trial, Chinese patients were prospectively randomly as...
clinical trialglucagon‐like peptide‐1 analoguephase III studytype 2 diabetesAim: To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI], and nonfatal stroke) and hospitalization for heart...
ObjectiveTo evaluate the efficacy and safety of oral semaglutide versus sitagliptin in Chinese patients with type 2 diabetes mellitus(T2DM) inadequately controlled with metformin. MethodsThe PIONEER 12 study was a phase Ⅲ clinical trial. Chinese patients were prospectively randomized to oral semaglutide...
OASIS-1 showed that "oral semaglutide 50 mg may represent an effective option for the treatment of obesity, particularly in patients who prefer oral administration," Knop summarized. And "the PIONEER PLUS trial showed superior glycemic control and body-weight loss and improvement in cardiometabolic ...
cardiovascular outcomes trial GLP-1 receptor agonist kidney function renal function semaglutide Lay Summary Patients with type 2 diabetes (T2D) often develop chronic kidney disease. Semaglutide is a medicine used to treat T2D; previous studies have shown these medicines may also reduce the decline of...
Thus, pooled analyses of clinical trial data in patients with T2D suggest that semaglutide may reduce the rate of eGFR decline. 展开 关键词: cardiovascular outcomes trial GLP-1 receptor agonist kidney function renal function semaglutide DOI: 10.1016/j.kint.2022.12.028 年份: 2023 ...
[3]Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272-2281. [4]Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglu...